Dr Wong discusses the significance of the FDA’s accelerated approval of vusolimogene oderparepvec-wtpg plus nivolumab in unresectable advanced cutaneous melanoma.
Michael Wong, MD, PhD, FRPC
Advertisement
Articles by Michael Wong, MD, PhD, FRPC
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Sequencing, Access, and Eligibility Drive CAR T-Cell Therapy Decisions in Early Relapse Myeloma
2
FDA Grants Fast Track Designation to Varsetatug Masetecan for Relapsed/Refractory Metastatic Colorectal Cancer
3
FDA Grants Fast Track Designation to SYS6090 in Pretreated MSS/pMMR mCRC
4
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
5